Payment overview · 2025
General Payments
$58.43
3 reported records · 3 companies
Healthcare provider profile · identity verified
David J Ogun, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKEWOOD, NJ · NPI 1447350418
Verified facts
What the public records show
CMS Open Payments records show David J Ogun, MD received $58.43 in general payments during 2025 across 3 reported records.
Exact Sciences Corporation accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.44 | 41.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.12 | 31.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.87 | 27.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $58.43 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
267 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 543 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 284 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 56 |
| Metformin Hcl | Metformin Hcl | 268 | 73 |
| Eliquis | Apixaban | 267 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 56 |
| Gabapentin | Gabapentin | 223 | 45 |
| Losartan Potassium | Losartan Potassium | 218 | 54 |
| Sertraline Hcl | Sertraline Hcl | 204 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 42 |
| Furosemide | Furosemide | 200 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 50 |
| Omeprazole | Omeprazole | 196 | 46 |
| Alprazolam | Alprazolam | 166 | 35 |
| Simvastatin | Simvastatin | 166 | 33 |
| Potassium Chloride | Potassium Chloride | 158 | 30 |
| Lisinopril | Lisinopril | 156 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 38 |
| Trazodone Hcl | Trazodone Hcl | 113 | 29 |
| Ozempic | Semaglutide | 112 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 33 |
| Ezetimibe | Ezetimibe | 100 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 15 |
| Jardiance | Empagliflozin | 91 | 18 |
| Alendronate Sodium | Alendronate Sodium | 90 | 20 |
| Clonazepam | Clonazepam | 90 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 55 |
| Tramadol Hcl | Tramadol Hcl | 84 | 25 |
| Famotidine | Famotidine | 76 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 17 |
| Glimepiride | Glimepiride | 71 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 16 |
| Finasteride | Finasteride | 70 | 17 |
| Montelukast Sodium | Montelukast Sodium | 70 | 16 |
| Spironolactone | Spironolactone | 70 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 20 |
| Allopurinol | Allopurinol | 67 | 14 |
| Mupirocin | Mupirocin | 62 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | 13 |
| Mirtazapine | Mirtazapine | 57 | 15 |
| Nystatin | Nystatin | 54 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 18 |
| Atenolol | Atenolol | 52 | 14 |
| Fluconazole | Fluconazole | 52 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Vancomycin Hcl | Vancomycin Hcl | 51 | suppressed |
| Colchicine | Colchicine | 50 | suppressed |
| Levofloxacin | Levofloxacin | 50 | 28 |
| Lorazepam | Lorazepam | 49 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 11 |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 41 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Glipizide | Glipizide | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 42 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 41 | 11 |
| Carvedilol | Carvedilol | 40 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Procrit | Epoetin Alfa | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 11 |
| Latanoprost | Latanoprost | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Prednisone | Prednisone | 31 | 19 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 21 |
| Lactulose | Lactulose | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Mesalamine | Mesalamine | 27 | suppressed |
| Methadone Hcl | Methadone Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Gemtesa | Vibegron | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 11 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58.43 · 3 records | Exact Sciences Corporation | ABRYSVO, COMIRNATY, Cologuard Collection Kit, Ozempic, PREVNAR 20, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error